EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials
Articolo
Data di Pubblicazione:
2020
Abstract:
Results of several randomized clinical trials (RCTs) testing the combination of an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) plus an anti-angiogenic drug in advanced EGFR-mutated non-small cell lung cancer were reported.
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
Conforti, Fabio; Pala, Laura; Bagnardi, Vincenzo; Specchia, Claudia; Oriecuia, Chiara; Marra, Antonio; Zagami, Paola; Morganti, Stefania; Tarantino, Paolo; Catania, Chiara; De Marinis, Filippo; Queirolo, Paola; De Pas, Tommaso
Link alla scheda completa:
Pubblicato in: